Postamputation femur reconstruction with an autologous vascularized tibia bone graft

Kempný, Tomáš; Holoubek, Jakub; Abdelkarim, Ahmad; Lipový, Břetislav; Knoz, Martin

doi:10.1002/micr.30441

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone defects caused by severe trauma, infection, tumor resection, or developmental deformity have remained a significant challenge for orthopedists and are both an economical and mental burden for patients. , Autologous bone grafts are considered the “gold standard” to treat bone defects and are the most commonly used treatment in clinics due to their more predictable postimplant outcomes, zero immunogenicity, and easy incorporation into the defective site. − However, autologous bone grafts are not available all the time, and associated complications, including poor bone union/nonunion, infection surrounding the implants, and invasive harvesting procedures, have restricted their application. ,, …”

Section: Introductionmentioning

confidence: 99%

Immunomodulation of Telmisartan-Loaded PCL/PVP Scaffolds on Macrophages Promotes Endogenous Bone Regeneration

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Biomaterial–immune system interactions play an important role in postimplantation osseointegration to retain the functionality of healthy and intact bones. Therefore, appropriate osteoimmunomodulation of implants has been considered and validated as an efficient strategy to alleviate inflammation and enhance new bone formation. Here, we fabricated a nanostructured PCL/PVP (polycaprolactone/polyvinylpyrrolidone) electrospinning scaffold for cell adhesion, tissue ingrowth, and bone defect padding. In addition, telmisartan, an angiotensin 2 receptor blocker with distinct immune bioactivity, was doped into PCL-/PVP-electrospun scaffolds at different proportions [1% (TPP-1), 5% (TPP-5), and 10% (TPP-10)] to investigate its immunomodulatory effects and osteoinductivity/conductivity. Telmisartan-loaded scaffolds displayed in vitro anti-inflammatory bioactivity on lipopolysaccharide-induced M1 macrophages by polarizing them to an M2-like phenotype and exhibited pro-osteogenic properties on bone marrow-derived mesenchymal stem cells (BMSCs). Histological analysis and micro-CT results of a rat skull defect model also showed that the telmisartan-loaded scaffolds induced a higher M2/M1 ratio, less inflammatory infiltration, and better bone regenerative patterns. Furthermore, activation of the BMP2 (bone morphogenetic protein-2)-Smad signaling pathway was found to be dominant in telmisartan-loaded scaffold-mediated macrophage–BMSC interactions. These findings indicate that telmisartan incorporation with PCL/PVP nanofibrous scaffolds is a potential therapeutic strategy for promoting bone healing by modulating M1 macrophages to a more M2 phenotype at early stages of postimplantation.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunomodulation of Telmisartan-Loaded PCL/PVP Scaffolds on Macrophages Promotes Endogenous Bone Regeneration

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

Postamputation femur reconstruction with an autologous vascularized tibia bone graft

Cited by 1 publication

References 2 publications

Immunomodulation of Telmisartan-Loaded PCL/PVP Scaffolds on Macrophages Promotes Endogenous Bone Regeneration

Immunomodulation of Telmisartan-Loaded PCL/PVP Scaffolds on Macrophages Promotes Endogenous Bone Regeneration

Contact Info

Product

Resources

About